Back to companies

Mereo Biopharma Group Plc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Mereo Biopharma Group Plc (Mereo) is a biopharmaceutical company that develops therapies for rare diseases. The company's pipeline products includes Setrusumab (UX-143), an antibody, which treats osteogenesis imperfecta; Alvelestat (MPH966) for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD); Etigilimab (MPH313) is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains that which targets metastatic solid tumors; Navicixizumab (OMP305B83) which treats platinum-resistant ovarian cancer; Acumapimod (BCT197) for acute exacerbations of chronic obstructive pulmonary disease and Leflutrozole (BGS649) is an oral inhibitor of aromatase. The company operates in the US and the UK. Mereo is headquartered in London, England, the UK.

 Gain a 360-degree view of Mereo Biopharma Group Plc and make more informed decisions for your business Gain a 360-degree view of Mereo Biopharma Group Plc and make more informed decisions for your business Register your interest
Headquarters United Kingdom
Address 4th Floor, 1 Cavendish Place, London, England, W1G0QF
Website www.mereobiopharma.com
Telephone 44 333 0237300
No of Employees 39
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange MREO (NASD)
Revenue (2024) $500,000
EPS XYZ
Net Income (2024) XYZ 3.2% (2024 vs 2023)
Market Cap* $39.1M
Net Profit Margin (2024) XYZ 0.0% (2024 vs 2023)
* As of and is in US$
View Mereo Biopharma Group Plc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Products and Services

Products
Pipeline
Setrusumab (UX-143): Osteogenesis Imperfecta
Alvelestat (MPH966): Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD)
XYZ
XYZ
XYZ
Understand Mereo Biopharma Group Plc portfolio and identify potential areas for collaboration Understand Mereo Biopharma Group Plc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Mereo Biopharma Group Plc Sanofi Grifols SA Krystal Biotech Inc Beam Therapeutics Inc
Headquarters United Kingdom France Spain United States of America United States of America
City London Paris Sant Cugat Del Valles Pittsburgh Cambridge
State/Province England Ile-de-France Barcelona Pennsylvania Massachusetts
No. of Employees 39 76,493 23,822 295 511
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Michael Wyzga Chairman Executive Board 2019 71
Denise Scots-Knight Chief Executive Officer; Director Executive Board 2015 67
Christine Fox Chief Financial Officer Senior Management 2021 44
John Lewicki Chief Scientific Officer Senior Management 2020 73
Charles Sermon General Counsel - Business Development; Secretary Senior Management 2015 55
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Mereo Biopharma Group Plc key executives to enhance your sales strategy Gain insight into Mereo Biopharma Group Plc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?